Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Irinotecan (CPT-11, camptosar)
3. Treatment of metastatic CRC
4. Safety of irinotecan (1)
5. Safety of irinotecan (2)
6. Illustration of metabolic pathway of irinotecan
7. Glucuronidation of SN-38 vs. toxicity
8. Schematic illustration of UGT1A
9. Candidate polymorphism: UGT1A1*28, (TA)7
10. UGT1A1*28 genotype-phenotype association (1)
11. UGT1A1*28 genotype-phenotype association (2)
12. Revised irinotecan package insert (Mar 2005)
13. Invader: UGT1A1molecular assay (Aug 2005)
14. Role of UGT1A1*28 in metastatic CRC
15. Unanswered questions
16. UGT1A1*28 frequency in 3 different ethnic groups
17. Another candidate polymorphism: UGT1A1*7
18. Frequency of UGT1A1*6 in Asians
19. UGT1A1*6 genotype-phenotype association
20. Efficacy in UGT1A1*28-genotyped patients
21. Irinotecan dose and hematologic toxicity
22. Individualization of chemotherapy
23. Genotype-based dosing of irinotecan (1)
24. Genotype-based dosing of irinotecan (2)
25. Role of other UGT1A
26. Metabolic pathway of irinotecan: transporters
27. Limitation of previous studies
28. Conclusions

Topics Covered

• Irinotecan activity and safety
• Metabolism of Irinotecan
• Structure of UGT1A
• Role of UGT1A1*28 on irinotecan pharmacogenetics
• Role of UGT1A1*6 in Asians
• Genotype-based dosing of irinotecan
• Other candidates: UGT1A enzyme or transporter

Links

Series:

• Cancer Therapy

Categories:

• Cancer
• Clinical Practice
• Genetics & Epigenetics

Therapeutic Areas:

• Oncology

Talk Citation

Kim, T.W. (2009, January 6). UGT1A1 polymorphisms and irinotecan toxicity in colorectal cancer patients [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 18, 2024, from https://hstalks.com/bs/1122/.
Export Citation (RIS)

Publication History

• Published on January 6, 2009
• Archived on February 25, 2021

Financial Disclosures

• Prof. Tae Won Kim has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.